Neoadjuvant EGFR-TKI Therapy for EGFR-Mutant NSCLC: A Systematic Review and Pooled Analysis of Five Prospective Clinical Trials

PurposeThe role of neoadjuvant epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor (TKI) targeted therapy for patients with EGFR-mutant non-small cell lung cancer (NSCLC) has not been clarified. A pooled analysis of prospective clinical trials was conducted to evaluate the efficacy and...

ver descrição completa

Detalhes bibliográficos

Principais autores:	Li Sun, Yi-Jia Guo, Jun Song, Yan-Ru Wang, Shu-Ling Zhang, Le-Tian Huang, Jian-Zhu Zhao, Wei Jing, Cheng-Bo Han, Jie-Tao Ma
Formato:	Artigo
Idioma:	Inglês
Publicado em:	Frontiers Media S.A. 2021-01-01
coleção:	Frontiers in Oncology
Assuntos:	neoadjuvant non-small cell lung cancer efficacy safety epidermal growth factor receptor-tyrosine kinase inhibitors
Acesso em linha:	https://www.frontiersin.org/articles/10.3389/fonc.2020.586596/full
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!